Amgen is leveraging new drug developments to mitigate patent expirations and drive growth in 2026
Executive summary: Amgen announces strategy to use its emerging drug pipeline to offset upcoming patent expirations and target growth by 2026. The plan aims to preserve revenue streams and market position amid intense competition in the biotech sector.
Who is involved: Amgen leadership, investors, and regulatory agencies overseeing drug approvals.
Likely next: Upcoming clinical trial readouts and regulatory filings for pipeline candidates, plus potential partnership announcements.
Amgen has identified growth opportunities in its drug pipeline to counter the impending patent expirations impacting its revenue. By focusing on innovative treatments, the company aims to sustain its market position and financial performance despite competitive pressures in the healthcare sector.
Timeline
- — US consumers are still spending, but JPMorgan says the cushion against higher prices is thinning (Yahoo Finance)
- — Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure (Yahoo Finance)
Analysis — what this means
Likely next events
- Regulatory filings for pipeline drugs
- Clinical trial data releases
- Strategic collaborations
- Updated earnings guidance
Sectors affected
- Biotechnology
- Pharmaceuticals
Regulatory implications
- Need for FDA approval pathways
- Reimbursement strategy considerations
Historical parallels
- Roche's pipeline shift
- Pfizer's patent cliff response
Sources
Open the full interactive case file on Beyond →